<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01935635</url>
  </required_header>
  <id_info>
    <org_study_id>2014ZX10002002-002</org_study_id>
    <nct_id>NCT01935635</nct_id>
  </id_info>
  <brief_title>A Clinical Trial on HB-Vac Activated-DCs Combined With Peg-IFN or NAs in CHB</brief_title>
  <official_title>A Clinical Trial on Hepatitis B Vaccine Activated-DCs Combined With Peg-interferon or Nucleotide Analogs in Chronic Hepatitis B</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Third Affiliated Hospital, Sun Yat-Sen University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Ruijin Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Second People's Hospital of Yunnan Province</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Third Affiliated Hospital, Sun Yat-Sen University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to investigate whether HB-Vac Activated-DCs Combined With
      Peg-IFN or NAs has more efficacy than Peg-IFN or NAs alone in the treatment of chronic
      hepatitis B patients
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The 450 patients meeting the entry criteria are divided into 6 groups, the clinical trial
      procedure is divided into 3 parts, according to the following steps:

      Part1 (0-12W):

        1. The research objects will be grouped according to the principle of a multicenter,
           randomized, open, parallel controlled clinical trial, 300 cases of cell therapy groups
           (100 cases with PEG-IFN treatment, LdT treatment for 100 cases, ETV treatment for 100
           cases), 150 cases of control groups (PEG-IFN therapy in 50 cases, LdT therapy for 50
           cases, ETV treatment for 50 cases).

           Part2 (12-36W):

        2. Cell therapy groups: enter the HBsAg sensitized dendritic cells activated T cells (HBsAg
           Pulse DCs-T, HPDCs-T) immune therapy combined with interferon (IFN) or nucleoside
           analogues treatment (NAs), infusion of HPDC-T every 2 weeks for 1 time, total 12 times.

        3. Control groups: antiviral therapy used only (IFN or NAs).

           Part3 (36-72W):

        4. The observation stage: discontinuation of interferon in the treatment of 48 weeks; NAs
           cases will continue on treatment with NAs.

      HPDCs-T produced procedure:

      The first step: 1-7 days Monocytes will be isolated from peripheral blood of patients. The
      monocytes obtained will be then incubated in fresh serum-free AIM-V medium (Gibco) containing
      800U/ml of GM-CSF and 400U/ml of IL-4 (Peprotech) for 5 days. After 5 days of culture in
      vitro, The DCs induced will be cultured with a commercially available hepatitis B vaccine
      containing 10 ug of HBsAg (GSK) for 2 days.

      The second step: 8-14 days The hepatitis B vaccine sensitized DCs (HPDCs) (from the first
      step) will be sub-cultured with patient's own PBMCs for 7 days: HBsAg can be efficiently
      presented to PBMCs by DCs, with producing HBV specific CTLs and HTLs (HPDCs-T).

      The third step: 15 days The PBMCs (the second step) containing enough HPDCs-T will be
      transfused back into the patient.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2015</start_date>
  <completion_date type="Anticipated">June 2018</completion_date>
  <primary_completion_date type="Anticipated">June 2018</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>HBV makers</measure>
    <time_frame>01/01/2014-31/12/2016, total 6 times (3 years)</time_frame>
    <description>HBV DNA loads,HBsAg/HBsAb titer,HBeAg/HBeAb titer</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Coagulation tests</measure>
    <time_frame>01/01/2014-31/12/2016, total 6 times (3 years)</time_frame>
    <description>PT,PTA,INR</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>liver function</measure>
    <time_frame>01/01/2014-31/12/2016, total 6 times (3 years)</time_frame>
    <description>ALT,AST,Tbil,Alb</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>alpha-fetal protein</measure>
    <time_frame>01/01/2014-31/12/2016, total 4 times (3 years)</time_frame>
    <description>AFP;Biomarkers of hepatocellular carcinoma,one time every 24 weeks</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>B ultrasound or MRI examination of the liver</measure>
    <time_frame>01/01/2014-31/12/2016, total 2 times (3 years)</time_frame>
    <description>The examination is performed both at the end of the pre-experiment and the main experiment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Liver biopsy</measure>
    <time_frame>01/01/2014-31/12/2016, total 2 times (3 years)</time_frame>
    <description>The examination is performed both before and during experiment.</description>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Anticipated">450</enrollment>
  <condition>Chronic Hepatitis B</condition>
  <arm_group>
    <arm_group_label>HPDCs-T immune therapy combined with IFN</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>HPDCs-T immune therapy:one time every 2 weeks during 12 weeks to 36 weeks, about 2*105-1*106 cells per time,total 12 times; IFN therapy (Peg-IFN α-2b/2a):one time every 1 week according to the standards for 48 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>HPDCs-T immune therapy combined with ETV</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>HPDCs-T immune therapy:one time every 2 weeks during 12 weeks to 36 weeks, about 2*105-1*106 cells per time,total 12 times; Entecavir(ETV)therapy:0.5mg per day according guidelines for the treatment of chronic hepatitis B in the Asia Pacific Region</description>
  </arm_group>
  <arm_group>
    <arm_group_label>HPDCs-T immune therapy combined with LdT</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>HPDCs-T immune therapy:one time every 2 weeks during 12 weeks to 36 weeks, about 2*105-1*106 cells per time,total 12 times; Telbivudine(LdT)therapy:600mg per day according guidelines for the treatment of chronic hepatitis B in the Asia Pacific Region</description>
  </arm_group>
  <arm_group>
    <arm_group_label>IFN treatment</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>IFN therapy (Peg-IFN α-2b/2a):one time every 1 week according to the standards for 48 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ETV treatment</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Entecavir(ETV)therapy:0.5mg per day according guidelines for the treatment of chronic hepatitis B in the Asia Pacific Region</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LdT treatment</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Telbivudine(LdT)therapy:600mg per day according guidelines for the treatment of chronic hepatitis B in the Asia Pacific Region</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>HPDCs-T immune therapy</intervention_name>
    <description>HPDCs-T immune therapy:one time every 2 weeks during 12 weeks to 36 weeks, IV (in the vein), about 2*105-1*106 cells per time,total 12 times;</description>
    <arm_group_label>HPDCs-T immune therapy combined with IFN</arm_group_label>
    <arm_group_label>HPDCs-T immune therapy combined with ETV</arm_group_label>
    <arm_group_label>HPDCs-T immune therapy combined with LdT</arm_group_label>
    <other_name>The HBsAg sensitized dendritic cells activated T cells</other_name>
    <other_name>HBsAg Pulse DCs-T</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        serum hepatitis B surface antigen(HBsAg) positive for at least 6 months; HBV DNA loads≥
        104IU/ml(Roche Cobas); Containing the IFN treatment: 2ULN ≤ ALT ≤ 10ULN and TBil ≤ 2ULN;
        Containing the ETV/LdT treatment: 2ULN ≤ ALT and TBil ≤ 5ULN; All patients have not
        received antiviral treatment or immunotherapy for the last 6 months.

        Exclusion Criteria:

        superinfection or co-infection with hepatitis A, C, D, E, cytomegalovirus and HIV, or
        Epstein-Barr virus; other liver diseases such as alcoholic liver disease, drug-induced
        hepatitis, Wilson disease and autoimmune hepatitis; ascites or gastrointestinal bleeding or
        peptic ulcer or esophageal varix by electronic gastroscope examination; liver cirrhosis;
        severe bacterial or fungal infections; a history of diabetes or cardiac disease or
        hypertension or nephrosis; pregnant women.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yuehua Huang, Doctor</last_name>
    <role>Study Director</role>
    <affiliation>Deparment of Infectious Diseases, the Third Affiliated Hospital of Sun Yat-sen University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Yurong Gu, Doctor</last_name>
    <phone>+862085252019</phone>
    <email>guyr163@163.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Xiaojuan Wu, Bachelor</last_name>
    <phone>+862085253372</phone>
    <email>wuxiaojuan1988@163.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>The Third Affiliated Hospital of Sun Yat-sen University</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510630</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yurong Gu, Doctor</last_name>
      <phone>8620-85252702</phone>
      <email>guyr163@163.com</email>
    </contact>
    <contact_backup>
      <last_name>Yuehua Huang, Doctor</last_name>
      <phone>86-18922103516</phone>
      <email>huangyh53@sysu.edu.cn</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>The second people's hospital of yunnan province</name>
      <address>
        <city>Kunming</city>
        <state>Yunnan</state>
        <zip>650000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jia Wei, Doctor</last_name>
      <phone>008613888229825</phone>
      <email>wejia@aliyun.com</email>
    </contact>
    <contact_backup>
      <last_name>Suqiong Li</last_name>
      <phone>008613888513029</phone>
      <email>ynlisq@163.com</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Ruijin Hospital Affiliated to Shanghai Jiaotong University School of Medicine</name>
      <address>
        <city>Shanghai</city>
        <zip>200000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wei Cai</last_name>
      <phone>008613611733071</phone>
      <email>carieyc@hotmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Qing Guo</last_name>
      <phone>0013901922856</phone>
      <email>guoqing8@sh163.net</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>April 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 1, 2013</study_first_submitted>
  <study_first_submitted_qc>September 4, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 5, 2013</study_first_posted>
  <last_update_submitted>April 26, 2017</last_update_submitted>
  <last_update_submitted_qc>April 26, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 28, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Third Affiliated Hospital, Sun Yat-Sen University</investigator_affiliation>
    <investigator_full_name>Yuehua Huang</investigator_full_name>
    <investigator_title>director of liver disease laboratory</investigator_title>
  </responsible_party>
  <keyword>CHB</keyword>
  <keyword>Antiviral</keyword>
  <keyword>Dentritic cells</keyword>
  <keyword>Immune Therapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis, Chronic</mesh_term>
    <mesh_term>Hepatitis B</mesh_term>
    <mesh_term>Hepatitis B, Chronic</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

